Daval International Limited Release: Results From an Open Label Clinical Study of AIMSPRO in the Treatment of Progressive Multiple Sclerosis to be Presented at the 2013 Annual Meeting of the Consortium of Multiple Sclerosis Centers, May 29-June 1

Published: May 28, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Eastbourne, UK – Daval International limited (“Daval International” or “Daval”), the UK based biotechnology company focused on the development of its leading product AIMSPRO®, announces that Dr Christopher Moore, from the Department of Clinical Neurophysiology, University of Portsmouth UK will present a poster at The 2013 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and the Fifth Cooperative Meeting with Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) which will be held on May 29 - June 1, 2013 at the Hilton Orlando Hotel in Orlando.

Dr Moore will present data from a centralized retrospective analysis of clinical outcomes from 154 patients with progressive multiple sclerosis treated with subcutaneous injections of hyperimmune caprine sera (AIMSPRO®). The analysis is based on self and physician-reported clinical efficacy measures in the 140 patients with documented follow-up/assessments with more detailed clinical scoring used in the follow-up of 14 patients.

The CMSC annual meeting brings together healthcare professionals and researchers involved in MS clinical care or research who are committed to improving the lives of people with MS. The goal of the Annual Meeting is to provide the most up-to-date information impacting all facets of MS patient care.

The title, timing and location of Dr Moore’s presentation are:

Poster No. SC23

Title: Clinical Benefits with AIMSPRO® in progressive multiple sclerosis: Open Label Study

Presented by: Dr Christopher Moore, Portsmouth, England

Session: Basic Science (poster)

Date: Thursday May 30 2013

Presentation time: 7.00 pm to 8:30 pm EDT

The abstract will be available for download on Daval International’s website by May 31, 2013, 07:00 am GMT, see www.davalinternational.com

For further information please contact:

Daval International Ltd

James Shotton +1 303 588 5881 or +44 (0)7739 648401

Chief Executive

NM Rothschild

Julian Hudson +44 (0)20 7280 5000

FTI Consulting

Julia Phillips / Simon Conway +44 (0)20 7831 3113


AIMSPRO® (Hyperimmune Caprine Sera, HICS) is a proprietary, purified, protein–multi-peptide conjugate complex being developed as a novel, first-in-class biological treatment for a number of immune diseases where regulation and stabilisation of the immune system is required. It is believed that the drug has a unique mechanism of action that supports its broad potential application in neuro-degenerative diseases. AIMSPRO has been granted a Specials License by the UK's MHRA and is also available in Australia under Categories A and B of the TGA's Special Access Scheme.

About Daval International Limited

Daval International Limited is a UK based biotechnology company focused on the development of its leading product AIMSPRO® as a novel treatment for serious unmet medical needs through a combination of innovation, dedication, skilled science, entrepreneurship and partnership. From its inception in 2000, the management team of Daval have had a vision of making available effective treatments that noticeably improve the quality of life of patients suffering from the most serious debilitating neuro-degenerative, inflammatory and autoimmune diseases and to offer a choice over and above some of the disease modifying treatments available currently.

Help employers find you! Check out all the jobs and post your resume.

Back to news